About two weeks after announcing success in the first Phase III trial of its platelet drug fostamatinib in chronic/persistent immune thrombocytopenia, Rigel Pharmaceuticals Inc. announced a 38% staff reduction, more or less gutting its R&D division to add a nearly equivalent headcount in commercial personnel.
As part of the Sept. 15 announcement, Rigel reported the retirement of board member and Executive VP of Discovery and...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
